SAGE - セ―ジ・セラピュ―ティクス (Sage Therapeutics Inc.) セ―ジ・セラピュ―ティクス

 SAGEのチャート


 SAGEの企業情報

symbol SAGE
会社名 Sage Therapeutics Inc (セ―ジ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 サゲ・セラピューティクス(SAGE Therapeutics Inc.)は臨床段階のバイオ製薬企業である。同社は生命を脅かすまれな中枢神経系(CNS)障害の治療のための治療法の開発・商業化に焦点を当てる。同社の最初の製品候補であるSAGE-547はガンマ - アミノ酪酸 - A(GABAA)受容体のシナプスおよびシナプス調整剤として作用するニューロステロイドであるアロプレグナノロンの静脈内製剤である。同社の次世代製品候補であるSAGE-217およびSAGE-689は、GABA A受容体系を標的とする。同社はCNSシナプスおよびシナプス外受容体の選択的アロステリック調節に基づいて薬物を開発することに焦点を当てる。同社の化学基盤は、GABAAまたはN-メチル-D-アスパラギン酸またはN-メチル-D-アスパラギン酸(NMDA)受容体のアロステリックモジュレータである内因性・化学的に修飾された合成神経活性ステロイド化合物の化学骨格に焦点を当てる。   セ―ジ・セラピュ―ティクスは米国のバイオ医薬品企業。2010年設立。生命を脅かす中枢神経系障害を治療する薬の開発、商品化に焦点を当てる主要プログラムのSAGE-547は、超難治てんかん重積状態の臨床開発中の製品候補。また、AGE-689とSAGE-217もてんかん治療の製品候補。   Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. The Company is pursuing new pathways with the goal of improving brain health, and its depression, neurology and neuropsychiatry franchise programs aim to change how brain disorders are thought about and treated. Its mission is to make medicines that matter so people can get better, sooner.
本社所在地 215 First Street Cambridge MA 02142 USA
代表者氏名 Kevin P. Starr ケヴィン・P・スター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-299-8380
設立年月日 40269
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 257人
url www.sagerx.com
nasdaq_url https://www.nasdaq.com/symbol/sage
adr_tso
EBITDA EBITDA(百万ドル) -244.32400
終値(lastsale) 134.75
時価総額(marketcap) 6288013886
時価総額 時価総額(百万ドル) 5707.977
売上高 売上高(百万ドル) 90.00000
企業価値(EV) 企業価値(EV)(百万ドル) 4615.544
当期純利益 当期純利益(百万ドル) -234.71700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 SAGE Therapeutics Inc revenues increased from $0K to $90M. Net loss decreased 28% to $91.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest income (expense) net increase from $1.4M to $8.7M (income) Other income (expense) net increase from $25K (expense) to $24K (income).

 SAGEのテクニカル分析


 SAGEのニュース

   Rapid-acting Sage Therapeutics and Biogens zuranolone could alter way depression is treated, says GlobalData  2021/06/25 14:50:53 Global Data
Sage Therapeutics and Biogen have recently announced positive results from a pivotal Phase III trial for their novel, GABA A receptor allosteric modulator, antidepressant zuranolone. The post Rapid-acting Sage Therapeutics and Biogens zuranolone could alter way depression is treated, says GlobalData appeared first on GlobalData .
   How Sage Therapeutics Beaten-Down Stock Could Come Back  2021/06/21 14:19:00 Barron''s
Jefferies analyst Andrew Tsai called the stocks swoon last week an overreaction. It should recover within the next three to six months, he said.
   What Happened to Sage Therapeutics Stock?  2021/06/21 10:21:00 The Motley Fool
Sage has been struggling for some time to bring its flagship antidepressant to the market.
   Here''s Why Sage Therapeutics Tanked This Week  2021/06/19 11:00:00 The Motley Fool
The neuroscience-focused biotech company didn''t give investors the result they wanted.
   Sage Therapeutics: Should You Buy This Beaten-Down Stock? Analyst Weighs In  2021/06/18 00:13:38 TipRanks
Some investors might love biotech stocks for their lottery ticket-like returns when a company strikes medical gold. A lottery ticket, however, costs only a buck or two
   The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations  2021/01/13 12:25:38 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 12) AbbVie Inc (NYSE: ABBV ) AcelRx Pharmaceuticals Inc (NASDAQ: ACRX ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) Alkermes Plc (NASDAQ: ALKS ) AtriCure Inc. (NASDAQ: ATRC ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) BIOLASE Inc (NASDAQ: BIOL ) (announced an agreement to expand laser adoption and hands-on training programs in targeted geographies) CareDx Inc (NASDAQ: CDNA ) Celsius Holdings, Inc. (NASDAQ: CELH ) DermTech Inc (NASDAQ: DMTK ) Dyne Therapeutics Inc (NASDAQ: DYN ) Edap Tms SA (NASDAQ: EDAP ) Evelo Biosciences Inc (NASDAQ: EVLO ) EXACT Sciences Corporation (NASDAQ: EXAS ) Eyenovia Inc (NASDAQ: EYEN ) Genetron Holdings Ltd – ADR (NASDAQ: GTH ) Guardant Health Inc (NASDAQ: GH ) (reacted to presentation at the JPMorgan Healthcare Conference) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) Kaleido Biosciences Inc (NASDAQ: KLDO ) Laboratory Corp.
   Canaccord Genuity Stick to Their Buy Rating for SAGE Therapeutics By Investing.com  2021/01/13 09:03:55 Investing.com
Canaccord Genuity Stick to Their Buy Rating for SAGE Therapeutics
   Sage Therapeutics Provides 2021 Corporate Strategy Update at J.P. Morgan Healthcare Conference  2021/01/07 11:30:00 Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $SAGE #Sage--Sage Therapeutics, Inc. (NASDAQ: SAGE), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain, today announced that Chief Executive Officer, Barry Greene, will discuss the Company’s progress in becoming a leader in brain health in a corporate presentation at the 39th Annual J.P. Morgan Healthcare Conference. As part of the presentation, Mr. Greene will hi
   The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica  2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
   Alnylam trailblazer Barry Greene makes the jump to the helm of a struggling Sage Therapeutics. Can he deliver another comeback?  2020/12/16 12:03:37 Endpoints News
Sage Therapeutics will look to a new chief to lead the way during its comeback attempt. Former Alnylam president Barry Greene — a well known fixture in the Boston/Cambridge hub — is taking the helm of the neuro outfit, just 6 weeks after the nearby Biogen stepped up with a

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セ―ジ・セラピュ―ティクス SAGE Sage Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)